Crossmark

Immunotherapy in patients with metastatic castration-resistant prostate cancer: a meta-analysis of data from 7 phase III studies and 3 phase II studies

Crossref DOI link: https://doi.org/10.1186/s40164-022-00312-y

Published Online: 2022-09-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Anqiang

Tong, Dali
Funding

Funding for this research was provided by:

Chongqing Municipal Public Health Bureau, Chongqing People's Municipal Government,China (2018QNXM041)

Chongqing Science and Technology Commission,China (cstc2018jcyjAX0645)
License Information

Text and Data Mining valid from 2022-09-26

Version of Record valid from 2022-09-26
More Information

Article History

Received: 29 June 2022

Accepted: 8 September 2022

First Online: 26 September 2022

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Institutional review board (IRB) approval for the study was obtained from the Ethics Committee on Clinical Investigation at Daping Hospital, Army Medical University.

: The authors agreed the MS publication.

: None declared.

Document is current

Any future updates will be listed below